Medivo Inc. today announced that it has acquired OnTrack Diabetes as part of the company’s continued focus to help physicians with patient treatment and care. This top-rated app will be instrumental in helping physicians coordinate patient care and can be recommended to monitor key clinical changes between office visits.
The free, highly rated app helps diabetics manage their diabetes by tracking various items such as blood glucose, food intake, medication, blood pressure (BP), pulse, exercise and weight. The app also produces charts, graphs and reports for optimal care coordination. The OnTrack app has been downloaded by more than a half million users and it has an average rating of 4.5 stars (based on 4,000 user reviews) in Google Play. It is available for Android devices.
“We are extremely excited about adding the powerful OnTrack Diabetes app as a resource for patients to monitor their symptoms and to create reports that can be shared with their physician,” said Sundeep Bhan, Chief Executive Officer and a Co-Founder of Medivo. “This acquisition also fits with our growth strategy, enhances our consumer app portfolio and furthers our plans to develop new patient and physician engagement services.”
OnTrack Diabetes was developed by GExperts Inc. of Newmarket, Ontario. The app’s features include an easy-to-use interface that simplifies adding new entries, a variety of useful graphs and reports, a detailed log book that is easily shared with a physician and a functional reminder program that can be set to alert users to glucose test two hours after eating.The OnTrack Diabetes app adds to Medivo’s mobile app portfolio, which includes apps for the management of inflammatory bowel disease (IBD) / Crohn’s and ulcerative colitis; hereditary angioedema (HAE), and chronic myelogenous leukemia (CML). Medivo’s apps allow patients to easily track symptoms, view recent lab results and communicate with fellow patients in real-time.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts